+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Fusion Inhibitor"

From
HIV Drugs Market Report 2025 - Product Thumbnail Image

HIV Drugs Market Report 2025

  • Report
  • March 2025
  • 175 Pages
  • Global
From
From
HIV Treatment Drugs Market in Africa 2024-2028 - Product Thumbnail Image

HIV Treatment Drugs Market in Africa 2024-2028

  • Report
  • July 2024
  • 162 Pages
  • Africa
From
Fusion Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Fusion Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
HIV Drugs Market Report and Forecast 2023-2031 - Product Thumbnail Image

HIV Drugs Market Report and Forecast 2023-2031

  • Report
  • May 2023
  • 160 Pages
  • Global
From
  • 9 Results (Page 1 of 1)
Loading Indicator

The Fusion Inhibitor market is a subset of the HIV/AIDS Drugs market. Fusion Inhibitors are a type of antiretroviral drug used to treat HIV/AIDS. They work by blocking the fusion of the HIV virus with the host cell, thus preventing the virus from entering the cell and replicating. Fusion Inhibitors are usually used in combination with other antiretroviral drugs to maximize their effectiveness. Fusion Inhibitors are generally well tolerated and have few side effects. They are also relatively easy to administer, as they are usually taken orally. However, they are not as effective as other antiretroviral drugs, and may not be suitable for all patients. Some of the companies in the Fusion Inhibitor market include Gilead Sciences, Merck, ViiV Healthcare, and Bristol-Myers Squibb. Show Less Read more